行情

PRTK

PRTK

Paratek生物制药
NASDAQ

实时行情|Nasdaq Last Sale

3.500
+0.060
+1.74%
盘后: 3.500 0 0.00% 16:06 02/18 EST
开盘
3.460
昨收
3.440
最高
3.520
最低
3.410
成交量
39.96万
成交额
--
52周最高
7.39
52周最低
2.660
市值
1.15亿
市盈率(TTM)
-0.9128
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

PRTK 新闻

  • 美国财政部宣布制裁俄罗斯石油公司一下属企业
  • 中国新闻网.20分钟前
  • 英国将采用积分移民制 对低技能移民说不
  • 新浪财经.31分钟前
  • 旅游、贸易遭疫情重创 新加坡下调今年经济增长预期
  • 参考消息.1小时前
  • 在华日资汽车厂家部分复工 人员返城受限致人手不足
  • 参考消息.1小时前

更多

所属板块

生物技术和医学研究
+0.77%
制药与医学研究
-0.10%

热门股票

名称
价格
涨跌幅

PRTK 简况

Paratek Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections. Sarecycline is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Its other product candidates are tetracycline-derived, molecular entities and are designed to utilize the recognized immune-modulation, anti-inflammatory and other beneficial properties of the tetracycline class. These research stage programs include product candidates for multiple sclerosis, spinal muscular atrophy, systemic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel diseases.
展开

Webull提供Paratek Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。